Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Idiopathic Hypersomnia
NCT06590662Phase 2Not yet recruiting
- Sponsor
- CHU Montpellier
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic hypersomnia (IH) comparing Solriamfetol with Placebo (2 arms). Primary endpoint: Idiopathic Hypersomnia Severity Scale at 7 weeks. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
solriamfetol
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT06590662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590662.